Printer Friendly

Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment.

BACKGROUND: Hepatocellular carcinoma (HCC), or liver cancer, is the third leading cause of cancer deaths worldwide, with prevalence 16-32 times higher in developing countries than in developed countries. Aflatoxin, a contaminant produced by the fungi Aspergillus flavus and Aspergillus parasiticus in maize and nuts, is a known human liver carcinogen.

OBJECTIVES: We sought to determine the global burden of HCC attributable to aflatoxin exposure.

METHODS: We conducted a quantitative cancer risk assessment, for which we collected global data on food-borne aflatoxin levels, consumption of aflatoxin-contaminated foods, and hepatitis B virus (HBV) prevalence. We calculated the cancer potency of aflatoxin for HBV-postive and HBV-negative individuals, as well as the uncertainty in all variables, to estimate the global burden of aflatoxin-related HCC.

RESULTS: Of the 550,000-600,000 new HCC cases worldwide each year, about 25,200-155,000 may be attributable to aflatoxin exposure. Most cases occur in sub-Saharan Africa, Southeast Asia, and China where populations suffer from both high HBV prevalence and largely uncontrolled aflatoxin exposure in food.

CONCLUSIONS: Aflatoxin may play a causative role in 4.6-28.2% of all global HCC cases.

KEY WORDS: aflatoxin, global disease burden, hepatitis, hepatocellular carcinoma, risk assessment. Environ Health Perspect 118:818-824 (2010). doi:10.1289/ehp.0901388 [Online 19 February 2010]

**********

Hepatocellular carcinoma (HCC), or liver cancer, is the third leading cause of cancer deaths worldwide [World Health Organization (WHO) 2008], with roughly 550,000-600,000 new HCC cases globally each year (Ferlay et al. 2004). Aflatoxin exposure in food is a significant risk factor for HCC (Wild and Gong 2010). Aflatoxins are primarily produced by the food-borne fungi Aspergillus flavus and Aspergillus parasiticus, which colonize a variety of food commodities, including maize, oilseeds, spices, groundnuts, and tree nuts in tropical and subtropical regions of the world. Additionally, when animals that are intended for dairy production consume aflatoxin-contaminated feed, a metabolite, aflatoxin [M.sub.1], is excreted in the milk (Strosnider et al. 2006).

Aflatoxins are a group of approximately 20 related fungal metabolites. The four major aflatoxins are known as [B.sub.1], [B.sub.2], [G.sub.1], and [G.sub.2]. Aflatoxins [B.sub.2], and [G.sub.2] are the dihydro-derivatives of the patent compounds [B.sub.1] and [G.sub.1] (Pitt and Tomaska 2001). Aflatoxin [B.sub.1] (AFB1) is the most potent (in some species) naturally occurring chemical liver carcinogen known. Naturally occurring mixes of aflatoxins have been classified as a Group 1 human carcinogen by the International Agency for Research on Cancer (IARC) and has demonstrated carcinogenicity in many animal species, including some rodents, nonhuman primates, and fish [International Programme on Chemical Safety (IPCS)/WHO 1998)]. Specific P450 enzymes in the liver metabolize aflatoxin into a reactive oxygen species (aflatoxin-8,9-epoxide), which may then bind to proteins and cause acute toxicity (aflatoxicosis) or to DNA to cause lesions that over time increase the risk of HCC (Groopman et al. 2008).

HCC as a result of chronic aflatoxin exposure has been well documented, presenting most often in persons with chronic hepatitis B virus (HBV) infection (Wild and Gong 2010). The risk of liver cancer in individuals exposed to chronic HBV infection and aflatoxin is up to 30 times greater than the risk in individuals exposed to aflatoxin only (Groopman et al. 2008). These two HCC risk factors--aflatoxin and HBV--are prevalent in poor nations worldwide. Within these nations, there is often a significant urban--rural difference in aflatoxin exposure and HBV prevalence, with both these risk factors typically affecting rural populations more strongly (Plymoth et al. 2009).

Aflatoxin also appears to have a synergistic effect on hepatitis C virus (HCV)-induced liver cancer (Kirk et al. 2006; Kuang et al. 2005; Wild and Montesano 2009), although the quantitative relationship is not as well established as that for aflatoxin and HBV in inducing HCC. Other important causative factors in the development of HCC, in addition to HBV or HCV infection and aflatoxin exposure, are the genetic characteristics of the virus, alcohol consumption, and the age and sex of the infected person (Kirk et al. 2006).

The IPCS/WHO undertook an aflatoxin-HCC risk assessment in 1998 to estimate the impact on population cancer incidence by moving from a hypothetical total aflatoxin standard of 20 ng/g to 10 ng/g (Henry et al. 1999; IPCS/WHO 1998). Assuming that all food containing higher levels of aflatoxin than the standard was discarded and that enough maize and nuts remained to preserve consumption patterns, IPCS/WHO determined that HCC incidence would decrease by about 300 cases per year per billion people, if the stricter aflatoxin standard were followed in nations with HBV prevalence of 25%. However, in. nations where HBV prevalence was 1%, the stricter aflatoxin standard would save only two HCC cases per year per billion people. This assessment associated HCC risk with particular doses of aflatoxin; however, these doses do not correspond with actual exposure in different parts of the world, and the two hypothetical values for HBV prevalence, 1% and 25%, were not intended to represent actual HBV prevalence worldwide.

Currently, > 55 billion people worldwide suffer from uncontrolled exposure to aflatoxin (Strosnider et al. 2006). What remains unknown is how many cases of liver cancer can be attributed to this aflatoxin exposure worldwide. Indeed, the Aflatoxin Workgroup (Strosnider et al. 2006), convened by the Centers for Disease Control and Prevention and WHO, identified four issues that warrant immediate attention: quantifying human health impacts and burden of disease due to aflatoxin exposure, compiling an inventory of ongoing intervention strategies, evaluating their efficacy, and disseminating the results.

Addressing this first issue is the aim of our study. We compiled available information on aflatoxin exposure and HBV prevalence from multiple nations in a quantitative cancer risk assessment, to estimate the number of HCC cases attributable to aflatoxin worldwide per year. Shephard (2008) estimated population risk for affaroxin-induced HCC in select African nations; we expand this to include the rest of the world. We briefly describe interventions that can either reduce aflatoxin directly in food or reduce adverse health effects caused by aflatoxin.

Materials and Methods

To perform a quantitative cancer risk assessment for aflatoxin-relatcd HCC, we analyzed extensive data sets by nation or world region: food consumption patterns (of maize and peanuts), aflatoxin levels in maize and peanuts, HBV prevalence, and population size. Risk assessment is the process of estimating the magnitude and the probability of a harmful effect to individuals or populations from certain agents or activities. Four steps are involved in estimation of the risk: hazard identification, dose-response analysis, exposure assessment, and risk characterization (National Research Council 1983).

Hazard identification. Hazard identification is the process of determining whether exposure to an agent can increase the incidence of a particular health condition. Aflatoxin exposure is associated with an increase in incidence of HCC in humans and sensitive animal species (Groopman et al. 2008); in fact, IARC has classified AFB1 naturally occurring mixes of aflatoxins as a Group 1 carcinogen (IARC 2002).

Dose--response analysis. This second risk assessment step involves characterizing the relationship between the dose of an agent--in this case, aflatoxin--and incidence of HCC. Because of the synergistic impact of aflatoxin and HBV in inducing HCC, the assessment must be done separately for populations with and without chronic HBV infection. Although chronic HCV infection may also have synergistic effects with aflatoxin in inducing HCC, we did not include this effect in the analyses for three reasons: a) there is much less overlap worldwide between aflatoxin and HCV exposures in general; b) chronic HCV infection usually occurs later in life, whereas chronic HBV infection occurs much earlier, thus the time of overlapped exposure is less significant for aflatoxin and HCV (Groopman J, personal communication); and c) much less is known about the quantitative relationship of aflatoxin and HCV in inducing HCC.

For cancer risk assessment, it is traditionally assumed that there is no threshold of exposure to a carcinogen below which there is no observable adverse effect (National Research Council 2008). Cancer potency factors are estimated from the slope of the dose-response relationship, which is assumed to be linear, between doses of the carcinogen and cancer incidence in a population. The IPSC WHO aflatoxin risk assessment selected two different cancer potency factors for aflatoxin: 0.01 cases/100,000/year/nanogram/kilogram body weight per day aflatoxin exposure for individuals without chronic HBV infection, and 0.30 corresponding cases for individuals with chronic HBV infection. This was based on one cohort study that estimated cancer potency in individuals positive for the HBV surface antigen (HBsAg; a biomarker of chronic HBV infection) and in HBsAg-negative individuals (Yeh et al. 1989), as well as other human studies that assessed cancer potency among either HBsAg-positive or HBsAg-negative individuals. We used these same potency factors for this risk assessment. Because only one of the studies (Yeh et al. 1989) specifically assessed cancer potency in both cohorts, considerable uncertainty may be associated with these potency factors. However, several epidemiological studies confirm that aflatoxin's cancer potency is about 30 times greater among HBV-positive than among HBV-negative individuals (Kirk et al. 2005, Ok et al. 2007; Qian et al. 1994).

Exposure assessment. Exposure assessment involves estimating the intensity, frequency, and duration of human exposures to a toxic agent. Specifically, we sought to determine how individuals' exposure to aflatoxin increases their risk of HCC. Aflatoxin exposure is a function not only of aflatoxin concentrations in maize and nuts but also of how much of these foodstuffs individuals consume in different parts of the world.

Aflatoxin exposure assessment has evolved significantly over the past two decades, largely due to the characterization of biomarkers for both aflatoxin exposure and effect (Groopman et al. 2005, 2008). Before these biomarkers, the primary way to estimate aflatoxin exposure was to observe how much maize and nuts people consumed on average and to measure or assume aflatoxin levels in these foods. By measuring biomarkers such as aflatoxin-albumin adducts in serum or aflatoxin-N7-guanine in urine, it is possible to improve estimations of aflatoxin exposure and how much has been biotransformed to increase cancer risk (Groopman et al. 2008).

Because aflatoxin biomarker data worldwide are limited, we collected data on estimated HBV prevalence in these countries and on maize and nut consumption patterns in different world regions and estimated average aflatoxin exposure or contamination levels in the maize and nuts in different world regions. Where aflatoxin exposure data were not already estimated, we used food consumption patterns and aflatoxin contamination levels to estimate exposure. The studies estimating HBV prevalence were based on HBsAg detection among males and among females in both urban and rural settings across all age groups. Data on maize and peanut consumption in different world regions are adapted from the WHO Global Environment Monitoring System (GEMS)/Food Consumption Cluster Diets database (WHO 2006). We estimated aflatoxin exposure data in different nations from multiple sources through literature searches.

Risk characterization. This final step of risk assessment integrates dose--response and exposure data to describe the overall nature and magnitude of risk. For our study, this final step consisted of quantifying, across the globe, the burden of aflatoxin-related liver cancer. For each nation, we estimated total number of individuals with or without chronic HBV by multiplying prevalence by population size. To estimate aflatoxin-induced HCC rates within these two populations (with and without chronic HBV infection), we multiplied the corresponding cancer potency factor by aflatoxin exposure estimates. Then we multiplied these values by each nation's HBV-positive and HBV-negative population sizes to derive total number of aflatoxin-induced HCC cases in each nation. We summed across all world regions to arrive at an estimate for global burden of aflatoxin-induced HCC.

Results

Table 1 lists the prevalence of chronic HBV infection by world region, as measured by HBsAg in different parts of the world. Although these different estimates involve uncertainty and variability, all data are from literature published in or after 2000, to ensure that the HBV prevalence estimates are as current and as relevant as possible. Countries are grouped by WHO designated regions (WHO 2005): Africa, North America and Latin America, Eastern Mediterranean, Southeast Asia, Western Pacific, and Europe. Some regions were divided into subgroups because of significantly varied aflatoxin exposure and HBV prevalence within the region.
Table 1. Estimates of HBV prevalence in select countries based on
HBsAg seroprevalence.

                                                        Chronic HBV
WHO                      References                     prevalence
region/country                                              (%)

Africa

Democratic       Batina et al. 2007; Mbendi et al.          6-10
Republic of      2001
Congo

Ethiopia         Abebe et al. 2003; Shimelis et al.         6-7
                 2008

The Gambia       Kirk et al. 2004; Vall et al. 1990        15-20

Kenya            Kiire 1996; Tuei 1994                     11-15

Mozambique       Cunha et al. 2007                        4.5-10.6

Nigeria          Fasola et al. 2008                         13.2

South Africa     Custer et al. 2004; Kiire 1996           3.3-10.4

Tanzania         Hasegawa et al. 2006; Matee et al.         5-9
                 2006; Miller et al. 1998

Zimbabwe         Kiire 1996; Tswana et al. 1996            10-15

Others           Kiire 1996; Matee et al. 2006; Tayou       9-20
                 et al. 2009

North America and Latin America

Canada           Minuk and Uhanova 2001; Zhang et al.       1-2
                 2001

United States    CDC 2009; Cohen et al. 2008; WHO         0.3-2
                 2005

Argentina        Parana and Almeida 2005; Torres 1996     0.8-1.1

Brazil           Parana and Almeida 2005; Torres 1996     2.1-3.4

Mexico           Roman et al. 2009                         $ 0.3

Others           Parana and Almeida 2005; Torres 1996     0.5-3

Eastern Mediterranean

Egypt            Ismail et al. 2009; Lehman and Wilson    2.2-10.1
                 2009; Youssef et al. 2009

Iran             Kafi-Abad et al. 2009(a), 2009(b)       0.41-0.56

Pakistan         Butt and Amin 2008; Khattak et al.         3.3
                 2002

Sudan            Elsheikh et al. 2007                       6-26

Others           Abou et al. 2009; Batayneh and Bdour    0.65-10
                 2002; Ameen et al. 2005; WHO 2005

Southeast Asia

India            Behal et al. 2008; Tandon et al. 1996    2.4-4.7

Indonesia        Hong et al. 2001; Merican et al. 2000;   2.5-5
                 van Hattum et al. 2003

Thailand         Tanprasert and Somjitta 1993             4.6-8

Others           Alam et al. 2007; All et al. 2009;         2-7
                 Jafri et al. 2006; WHO 2005

Western Pacific

Australia        WHO 2007                                   $ 1

China            Merican et al. 2000; WHO 2007              8-10

Malaysia         Merican et al. 2000; WHO 2007               5

Philippines      Domingo 1997; Lansang 1996; WHO 2007       5-16

Korea            Song et al. 2009; WHO 2007                 4-5

Others           Gust 1996; Merican et al. 2000;            1-10
                 Nakata et al. 1994

Europe

Eastern Europe   Magdzik 2000; Resuli et al. 2009           2-7

Southern Europe  Da Villa 1998; Gogos et al. 2003; WHO      2-7
                 2005

Western Europe   Hahne et al. 2004; WHO 2005; Jilg et     0.5-1
                 al. 2001

CDC, Centers for Disease Control and Prevention.


Table 2 provides calculations of maize and peanut consumption in select countries of the world. The GEMS/Food Consumption Cluster Diets database divides countries of the world into 13 groups based on diets. For each group cluster, the GEMS food consumption database has estimated the amount of cereals, nuts, and oilseeds consumed. We thus estimated average maize and nut consumption by individual country. There are limitations to these data because of the clustering into 13 groups (with potentially wide ranges among nations within a group), as well as variability in data quality regarding diet and aflatoxin exposure estimates.
Table 2. Maize and peanut consumption in select countries.

                                     Maize (a)       Peanut (b)
WHO region/country                (g/person/day)  (g/person/day)

Africa

Democratic Republic of Congo             57              52
Ethiopia                                 83              13
The Gambia                               57              52
Kenya                                   248              11
Mozambique                              248              11
Nigeria                                  57              52
South Africa                            248              11
Tanzania                                248              11
Zimbabwe                                248              11

North America and Latin America
Canada                                   86              17
United States                            86              17
Argentina                                86              17
Brazil                                   63               2
Mexico                                  300               5

Eastern Mediterranean
Egypt                                   136               5
Iran                                     32               2
Pakistan                                 35              18
Sudan                                    57              52

Southeast Asia
India                                    35              18
Indonesia                                35              18
Thailand                                 35              18

Western Pacific
Australia                                86              17
China                                    35              18
Malaysia                                 35              18
Philippines                              59               2
Republic of Korea                        59               2

Europe
Eastern Europe                           32            2-10
Southern Europe                         148               7
Western Europe                           33              10

Data are adapted from GEMS/Food Consumption Cluster Diets database
(WHO 2006).

(a) Including maize, flour and germ.

(b) including groundnuts in shell and shelled.


We estimated (based on Tables 1 and 2) or found in the literature the average aflatoxin exposure in different world regions and then calculated the estimated incidence of aflatoxin-induced HCC, with and without the synergistic impact with HBV, in the corresponding populations of each nation and world region (Table 3). Within each WHO-designated region, we found aflatoxin exposures in the most populous nations. The "in general" rows in Table 3 represent a small proportion of each region: nations in which aflatoxin data were not available, or very small nations. For these, we assumed a range for aflatoxin exposure that incorporated the ranges of the nations within the region for which we found aflatoxin data.
Table 3. Estimated HCC incidence attributable to aflatoxin, by WHO
region.

                                                        Aflatoxin
                                                         exposure
WHO                 Reference                           (ng/kg body
region/country                                        weight/day (a))

Africa

Democratic          Manjula et al. 2009 (b)              0.07-27
Republic of Congo

Ethiopia            Ayalew et al. 2006 (b)                1.4-36

The Gambia          Hall and Wild 1994; Shephard            4-115
                    2008

Kenya               Hall and Wild 1994; Shephard          3.5-133
                    2008

Mozambique          Hall and Wild 1994                     39-180

Nigeria             Bandyopadhyay et al. 2007;            139-227
                    Bankole and Mabekoje 2004 (b)

South Africa        Hall and Wild 1994; Shephard            0-17
                    2003

Tanzania            Manjula et al. 2009 (b)              0.02-50

Zimbabwe            IPCS/WHO 1998                        17.5-42.5

In general (c)      Hall and Wild 1994; Shephard           10-180
                    2008

North America

Canada              Kuiper-Goodman 1995                   0.2-0.4 (d)

United States       IPCS/WHO 1998                           0.26

In general (c)                                           0.26-1

Latin America

Argentina           Etcheverry et al. 1999; Solovey         0-4
                    et al. 1999 (b)

Brazil              IARC 2002; Midio et al. 2001;        0.23-50
                    Oliyeira et al. 2009; Vargas et
                    al. 2001 (b)

Mexico              Garcia and Heredia 2006;               14-85
                    Guzman-de-Pena and
                    Pena-Cabriales 2005; Torres et
                    al. 1995 (b)

In general (c)                                             20-50

Eastern Mediterranean

Egypt               Anwar et al. 2008 (b)                   7-57

Iran                Hadiani et al. 2009; Mazaheri           5-8.5
                    2009 (b)

Pakistan            Munir et al. 1989 (b)                   7-50

Sudan               Omer et al. 1998                       19-186

In general (c)                                             10-80

Southeast Asia

India               Vasanthi 1998                           4-100

Indonesia           Ali et al. 1998; IARC 2002;             9-122
                    Noviandi et al. 2001 (b)

Thailand            Hall and Wild 1994;                    53-73
                    Lipigorngoson et al. 2003 (b)

In general (c)                                             30-100

Western Pacific

Australia           NHMRC 1992; Pitt and Tomaska         0.15-0.18
                    2001

China               Li et al. 2001; Qian et al.            17-37
                    1994; Wang and Liu 2007; Wang
                    et al. 2001 (b)

Malaysia            Ali et al. 1999; IARC 2002 (b)         15-140

Philippines         Ali et al. 1999; IARC 2002;            44-54
                    Sales and Yoshizawa 2005 (b)

Republic of Korea   Ok et al. 2007; Park et al.           1.2-6
                    2004

In general (c)                                        15-50 (except
                                                        Australia
                                                         and New
                                                         Zealand)

Europe

Eastern Europe      Malir et al. 2006 (e)                 3.5-4

Southern Europe     Battilani et al. 2008; Giray et         0-4
                    al. 2007 (f)

Western Europe      IARC 2002                             0.3-1.3

In general (c)                                              0-4

                               Estimated annual HCC (per 100,000)

WHO region/country                HBsAg-negative  HBsAg-positive

Africa

Democratic Republic of Congo     0.0007-0.27       0.02-8.10

Ethiopia                           0.01-0.36       0.42-10.8

The Gambia                         0.04-1.15       1.20-34.5

Kenya                              0.04-1.33       1.05-39.9

Mozambique                         0.39-1.80       11.7-54.0

Nigeria                            1.39-2.27       41.7-68.1

South Africa                          0-0.17          0-5.10

Tanzania                         0.0002-0.50       0.06-15.0

Zimbabwe                           0.18-0.43       5.25-12.8

In general (c)                     0.10-1.80        3.0-54.0

North America

Canada                            0.002-0.004      0.06-0.12

United States                     0.003            0.08

In general (c)                    0.003-0.01       0.08-0.3

Latin America

Argentina                             0-0.04          0-1.20

Brazil                            0.002-0.50       0.07-15.0

Mexico                             0.14-0.85       4.20-25.5

In general (c)                     0.20-0.50        6.0-15.0

Eastern Mediterranean

Egypt                              0.07-0.57        2.1-17.1

Iran                               0.05-0.09       1.50-2.55

Pakistan                           0.07-0.50       2.10-15.0

Sudan                              0.19-1.86       5.70-55.8

In general (c)                     0.10-0.80       3.00-24.0

Southeast Asia

India                              0.04-1.00       1.20-30.0

Indonesia                          0.09-1.22        2.7-36.6

Thailand                           0.53-0.73       15.9-21.9

In general (c)                     0.30-1.00       9.00-30.0

Western Pacific

Australia                        -0.002           -0.05

China                              0.17-0.37       5.10-11.1

Malaysia                           0.15-1.4         4.5-42

Philippines                        0.44-0.54       13.2-16.2

Republic of Korea                  0.01-0.06       0.36-1.80

In general (c)                     0.15-0.50        4.5-15.0

Europe

Eastern Europe                     0.04           -1.20

Southern Europe                       0-0.04          0-1.20

Western Europe                    0.003-0.01       0.09-0.39

In general (c)                        0-0.04          0-1.2

NHMRC, National Health and Medical Research Council.

(a) Assuming 60 kg body weight per individual.

(b) Aflatoxin exposure was estimated by multiplying aflatoxin
concentrations in staple foods by consumption rates of those foods
(WHO 2006).

(c) Aflatoxin exposure estimates and consequent HCC cases for all
other countries classified in the same WHO region.

(d) Aflatoxin exposure of 1-2 ng/kg body weight/day was measured in
children's diets; here we assume the adult daily aflatoxin intake is
20% that of children.

(e) Average daily aflatoxin intake was estimated based on AFB1
contamination levels in Czech maize, multiplied by average daily
maize consumption in Eastern Europe.

(f) Average daily aflatoxin intake was estimated based on AFB1
contamination levels in maize of North Italy and Turkey, multiplied by
average daily maize consumption in Southern Europe.


These data provide the necessary information to calculate the total estimated cases of aflatoxin-induced HCC cases annually, worldwide. Table 4 lists populations for each relevant nation and world region. Accounting for chronic HBV infection prevalence as shown in Table 1, and the risk estimates for HBV-positive versus HBV-negative individuals in Table 3, the numbers of cases of aflatoxin-induced HCC can be estimated in each world region. These are then summed to produce a global estimate of the number of annual aflatoxin-induced HCC cases. Our estimate is that anywhere from 25,200 to 155,000 annual HCC cases worldwide may be attributable to aflatoxin exposure.
Table 4. Estimated annual globs burden of HCC cases attributable to
aflatoxin exposure in HBsAg-positive and HBsAg-negative populations.

                                              Annual HCC cases

WHO region/country      Population   HBsAg-negative   HBsAg-positive
                        (millions)
                           (a)

Africa

Democratic Republic         68           1-173            1-551
of Congo

Ethiopia                    85          11-288           21-643

The Gambia                   1.7         1-17             3-117

Kenya                       38          11-450           44-2,270

Mozambique                  21          73-361          111-1,200

Nigeria                    149       1,800-2,940      8,200-13,400

South Africa                48           0-79             0-255

Tanzania                    41           1-195            1-554

Zimbabwe                    13          19-50            68-249

 Total region              755       2,150-9,300      9,230-50,600

North America

Canada                      33           1                1

United States              300           8                1-5

 Total region              333           9                2-5

Latin America

Argentina                   40           0-16             0-5

Brazil                     190           4-930            3-969

Mexico                     109         152-924           14-83

 Total region              562         589-2,980         84-2,060

Eastern Mediterranean

Egypt                       81          51-452           37-1400

Iran                        66          33-56             4-9

Pakistan                   172         116-832          119-851

Sudan                       41          58-717          140-5,950

 Total region              569         446-3,720        341-13,200

Southeast Asia

India                    1,150         438-11,200       331-16,200

Indonesia                  237         203-2,820        160-4,340

Thailand                    63         307-439          461-1,100

 Total region           -1,734       1,740-17,300     1,460-27,600

Western Pacific region

Australia                   21           0-1              0-1

China                    1,300       1,990-4,430      5,300-14,400

Korea                       50           5-29             6-45

Malaysia                    28          40-372           63-588

Philippines                 90         333-462          594-2,330

 Total region           -1,740       2,710-6,510      6,310-21,200

Europe

Eastern Europe             290          94-114           61-244

Southern Europe            144           0-56             0-121

Western Europe             183           5-24             1-7

 Total region              617          99-184           62-372

Total (world)            6,280       7,700-40,000    17,500-115,000

 Total annual HCC                   25,200-155,000
  cases attributable to
  aflatoxin worldwide

(a) Data from Central Intelligence Agency 2009.


Figure 1 illustrates the distribution of HCC cases attributable to aflatoxin globally. The categories denote WHO world regions. Sub-Saharan Africa is the most important region for HCC cases attributable to aflatoxin; Southeast Asia and China (in the Western Pacific region) are also key regions where aflatoxin-related HCC is an important risk. Relatively fewer cases occur in the Americas, Eastern Mediterranean, and Europe. Although Australia and New Zealand are grouped with the Western Pacific region, these nations also have low aflatoxin-induced HCC incidence. It is notable that in Mexico, where HBV prevalence is relatively low but aflatoxin contamination in food is relatively high, aflatoxin appears to be a significant risk factor for HCC among those without HBV (an estimated 152-924 HCC cases per year per 100,000 people).
Figure 1. Distribution of HCC cases attributable to aflatoxin in
different regions of the world.

Africa                 40%
North America           0%
Latin America           3%
Eastern Mediterranean  10%
Southeast Asia         27%
Western Pacific        20%
Europe                  0%

Note: Table made from pie chart.


Discussion

Aflatoxin contamination in food is a serious global health problem, particularly in developing countries. Although it has been known for several decades that aflatoxin causes liver cancer in humans, the exact burden of aflatoxin-related HCC worldwide was unknown. This study represents a first step in attempting to estimate that burden. We find that at its lower estimate, aflatoxin plays a role in about 4.6% of total annual HCC cases; at its upper estimate, aflatoxin may play a role roughly 28.2% of all HCC cases worldwide. This large range stems from the considerable uncertainty and variability in data on cancer potency factors, HBV prevalence, aflatoxin exposure, and other risk factors in different world regions. The most heavily afflicted parts of the world are sub-saharan Africa, Southeast Asia, and China.

As indicated in Table 3, populations in developing countries in tropical and subtropical areas are nearly ubiquitously exposed to moderate to high levels of aflatoxin. Aflatoxin is a controllable risk factor in food, yet the parts of the world in which the risk is particularly high have limited resources to implement most aflatoxin control strategies. Much agricultural land in Africa and Asia lies in climatic regions favorable for A. flavus and A. parasiticus proliferation. Suboptimal field practices and poor drying/storage conditions make crops vulnerable to fungal infection and aflatoxin accumulation. Maize and groundnuts, the two crops most conducive to Aspergillus infection, are staples in many African and Asian diets. Because the very poor in these regions cannot afford much food variety, these staples make up a significant portion of their diets, increasing aflatoxin exposure.

Even within the same nation, aflatoxin-induced HCC risk can vary significantly among different populations, hence the large national ranges for risk shown in Table 4. Rural populations generally have higher levels of aflatoxin exposure than do urban dwellers in developing countries (Wild and Hall 2000), because urban populations typically consume more diversified diets than do rural dwellers and may have food that is better controlled for contaminants. In addition, there is a strong seasonal variation in aflatoxin exposure that correlates with food availability (Gnonlonfin et al. 2008; Tajkarimi et al. 2007). Moreover, HBV prevalence is generally higher in rural areas than in urban ones, and higher among males than among females in most places (Plymoth et al. 2009). We present our collected data of HBsAg seroprevalence as a range for countries or populations (Table 1), to account for these variations.

Although many nations that suffer from both high aflatoxin exposures and high HBV prevalence have nominally established maximum allowable aflatoxin standards in food, there is little if any enforcement of these standards in many rural areas. Indeed, the food in subsistence farming and local food markets is rarely formally inspected. Strict aflatoxin standards can even lead to large economic losses for poor food-exporting nations when trading with other nations (Wu 2004). Subsistence farmers and local food traders sometimes have the luxury of discarding obviously moldy maize and groundnuts. Bur in drought seasons, oftentimes people have no choice but to eat moldy food or starve (Williams 2008).

Multiple public health interventions exist to control the burden of aflatoxin in the body and to prevent HCC. These interventions, described in greater detail in Wu and Khlangwiset (2010), can be grouped into three categories: agricultural, dietary, and clinical. Agricultural interventions can be applied either in the field (preharvest) or in storage and transportation (postharvest) to reduce aflatoxin levels in key crops. They can thus be considered primary interventions. Dietary and clinical interventions can be con-sidered secondary interventions. They cannot reduce actual aflatoxin levels in food, but they can reduce aflatoxin-related illness, either by reducing aflatoxin's bioavailability in the body or by ameliorating aflatoxin-induced damage. Because aflaroxin-mediated mutations may precede HCC by several years, the effects of reducing aflatoxin exposure on HCC incidence may take time to become apparent (Szymanska et al. 2009).

One highly effective clinical intervention to reduce aflatoxin-related HCC is vaccination against HBV. Vaccinating children against HBV has, over the past 30 years, significantly decreased HBV infection in several regions, including Europe (Bonanni et al. 2003; Williams et al. 1996), Taiwan (Chen et al. 1996), and Thailand (Jutavijittum et al. 2005). This vaccine will, over time, lessen the global carcinogenic impact of aflatoxin, because removing the synergistic impact between HBV and aflatoxin exposure would significantly reduce HCC risk. However, there are currently roughly 360 million chronic HBV carriers worldwide, and HBV vaccination is still not incorporated into many national immunization programs (Wild and Hall 2000). Thus, adopting measures to reduce dietary exposure to aflatoxins is crucial for public health.

Our study highlights the significant role of aflatoxin in contributing to global liver cancer burden. Most cases occur in sub-Saharan Africa, Southeast Asia, and China, where populations suffer from both high HBV prevalence and largely uncontrolled exposure to aflatoxin in the food. Not all risk factors for HCC, including synergistic roles between aflatoxin and other carcinogens, are clearly understood; hence, these estimates for number of global aflatoxin-induced HCC cases have a large range. Although it is impossible to completely eliminate aflatoxin in food worldwide, it is possible to significantly reduce levels and dramatically reduce liver cancer incidence worldwide. The challenge remains to deliver these interventions to places of the world where they are most needed.

REFERENCES

Abebe A, Nokes DJ, Dejene A, Enquselassie F, Messele T, Cutts FT. 2003. Seroepidemiology of hepatitis B virus in Addis Ababa, Ethiopia; transmission patterns and vaccine control. Epidemiol Infect 131(1):757-770.

Abou M, Eltahir Y, Ali A. 2009. Seroprevalence of hepatitis B virus and hepatitis C virus among blood donors in Nyala, South Dar Fur, Sudan. Virol J 6:146; doi:10.1186/1743-422X-6-146 [Online 23 September 2009].

Alam M, Zaidi S, Malik S, Naeem A, Shaukat S, Sharif S, et al. 2007. Serology based disease status of Pakistani population infected with Hepatitis B virus. BMC Infect Dis 7:64; doi:10.1186/1471-2334-7-64 [Online 27 June 2007].

Ali N, Hashim NH, Yoshizawa T. 1999. Evaluation and application of a simple and rapid method for the analysis of aflatoxins in commercial foods from Malaysia and the Philippines. Food Addit Contam Part A 16(7):273-280.

Ali N, Sardjono, Yamashita A, Yoshizawa T. 1998. Natural co-occurrence of aflatoxins and Fusavium mycotoxins (fumonisins, deoxynivalenol, nivalenol and zearalenone) in corn from Indonesia. Food Addit Contam Part A 15(4):377-384.

Ali SA, Donahue RMJ, Qureshi H, Vermund SH. 2009. Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors. Int J Infect Dis 13(1):9-19.

Ameen R, Sanad N, AI-Shemmari S, Siddique I, Chowdhury RI, AI-Hamdan S, et al. 2005. Prevalence of viral markers among first-time Arab blood donors in Kuwait. Transfusion 45(12):1973-1980.

Anwar WA, Khaled HM, Amra HA, El-Nezami H, Loffredo CA. 2008. Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention. Mutat Res 659(1-2):176-184.

Ayalew A, Fehrmann H, Lepschy J, Beck R, Abate D. 2006. Natural occurrence of mycotoxins in staple cereals from Ethiopia. Mycopathologia 162(1):57-63.

Bandyopadhyay R, Kumar M, Leslie JF. 2007. Relative severity of aflatoxin contamination of cereal crops in West Africa. Food Addit Contam: Part A 24(10):1109-1114.

Bankole SA, Mabekoje 00. 2004. Occurrence of aflatoxins and fumonisins in preharvest maize from south-western Nigeria. Food Addit Contam: Part A 21(3):251-255.

Batayneh N, Bdour S. 2002. Risk of perinatal transmission of hepatitis B virus in Jordan. Infect Dis Obstet Gynecol 10(3):127-132.

Batina A, Kabemba S, Malengela R. 2007. Infectious markers among blood donors in Democratic Republic of Congo (DRC). Rev Med Brux 28(3): 145-149.

Battilani P, Barbano C, Piva G. 2008. Aflatoxin Bl contamination in maize related to the aridity index in North Italy. World Mycotox J 1(4):449-456.

Behal R, Jain R, Behal KK, Bhagoliwal A, Aggarwal N, Dhole TN. 2008. Seroprevalence and risk factors for hepatitis B virus infection among general population in Northern India. Arq Gastroenterol 45(2):137-140.

Bonanni P, Pesavento G, Bechini A, Tiscione E, Mannelli F, Benucci C, et al. 2003 Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine 21(7-8):685-691.

Butt T, Amin M. 2008. Seroprevalence of hepatitis B and C infections among young adult males in Pakistan, East Mediterr Health J 14(4):791-797.

Centers for Disease Control and Prevention. 2009 Disease Burden from Viral Hepatitis A, B, and C n the United States. Available: http://www.cdc.gov/hepatitis/Statistics.htm#section 1 [accessed 5 November 2009].

Central Intelligence Agency. 2009. World Factbook. Available: https://www.cia.gov/library/publications/the-world-factbook/index.html [accessed 18 August 2009].

Chen H, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY, et al. 1996. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 276(11):906-908.

Cohen C, Evans AA, London WT, Block J, Conti M, Block T. 2008 Underestimation of chronic hepatitis B virus infection in the United States of America. J Viral Hepat 15(1):12-13.

Cunha L, Plouzeau C, Ingrand P, Gudo JPS, Ingrand I, Mondlane J, et al. 2007. Use of replacement blood donors to study the epidemiology of major blood-borne viruses in the general population of Maputo, Mozambique. J Med Virol 79(12): 1832-1840.

Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. 2004. Global epidemiology of hepatitis B virus. J Clin Gastroentorol 38(10 suppl 3):S158-S168.

Da Villa G, Piccinino, Scolastico C, Fusco M, Piccinino R, Sepe A. 1998. Long-term epidemiological survey of hepatitis B virus infection in a hyperendemic area (Afragola, southern Italy): results of a pilot vaccination project. Res Virol 149(5):263-270.

Domingo E. 1997. Chronic hepatitis B in the Philippines: problems posed by the hepatitis B surface antigen-positive carrier. In: Hepatitis B in the Asian-Pacific Region, vol. 1--Screening, Diagnosis and Control (Zuckerman A, ed). London:Royal College of Physicians, 103-113.

Elsheikh R, Daak A, Elsheikh M, Karsany M, Adam I 2007. Hepatitis B virus and hepatitis C virus in pregnant Sudanese women. Virol J 4:104; doi:10.1186/1743-422X-4-104 [Online 24 October 2007].

Etcheverry M, Nesci A, Barros G, Torres A, Chulze S. 1999. Occurrence of Aspergillus section Flavi and aflatoxin B1 in corn genotypes and corn meal in Argentina. Mycopathologia 147(1):37-41.

Fasola F, Kotila T, Akinyemi J. 2008. Trends in transfusion-transmitted viral infections from 2001 to 2006 in Ibadan, Nigeria. Intervirology 51(6):427-431.

Ferlay J, Bray F, Pisani P, Parkin DM. 2004. GLOBOCAN 2002: Cancer Incidence. Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0. Available: http://www.dep.iarc.fr. Available: http://www.dep.iarc.fr/globocan/downloads.htm [accessed 27 April 2010].

Garcia S, Heredia N. 2006. Mycotoxins in Mexico: epidemiology, management, and control strategies. Mycopathologia 162(3):255-264.

Giray B, Girgin G, Engin AB, Aydln S, Sahin G. 2007. Aflatoxin levels in wheat samples consumed in some regions of Turkey. Food Control 18(1):23-29; doi:10.1016/j.foodcont.2005.08.002 [Online 29 September 2005].

Gnonlonfin GJ, Hell K, Fandohan P, Siame AB. 2008. Mycoflora and natural occurrence of aflatoxins and fumonisin Bl in cassava and yam chips from Benin, West Africa. Int J Food Microbiol 122(1-2):140-147.

Gogos CA, Fouka KP, Nikiforidis G, Avgeridis K, Sakellaropoulos G, Bassaris H, et al. 2003. Prevalence of hepatitis B and C virus infection in the general population and selected groups in South-Western Greece. Eur J Epidemiol 18(6):551-557.

Groopman JD, Johnson D, Kensler TW. 2005. Aflatoxin and hepatitis B virus biomarkers: a paradigm for complex environmental exposures and cancer risk. Cancer Biomark 1(1):5-14.

Groopman JD, Kensler TW, Wild CP. 2008. Protective interventions to prevent aflatoxin-induced carcinogenesis in developing countries. Annu Rev Public Health 29:187-203.

Gust ID. 1996. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 38(suppl 2):S18-S23.

Guzman-de-Pena D, Pena-Cabriales JJ. 2005. Regulatory considerations of aflatoxin contamination of food in Mexico. Rev Latinoam Microbiol 47(3-4);160-164.

Hadiani M, Yazdanpanah H, Amirahmadi M, Soleimani H, Shoeibi S, Khosrokhavar R. 2009. Evaluation of aflatoxin contamination in maize from Mazandaran province in Iran. J Med Plants 8(suppl 5):109-114.

Hahne S, Ramsay NI, Balogun K, Edmunds WJ, Mortimer P. 2004. Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995-2000: implications for immunisation policy. J Clin Virol 29(4):211-220.

Hall AJ, Wild CP. 1994. Epidemiology of aflatoxin-related disease. In: The Toxicology of Aflatoxins: Human Health, Veterinary and Agricultural Significance (Eaton DA, Groopman JD, eds). San Diego, CA:Academia Press, 233-258.

Hasegawa I, Tanaka Y, Kurbanov F, Yoshihara N, El-Gohary A, Lyamuya E, et al. 2006. Molecular epidemiology of hepatitis B virus in the United Republic of Tanzania. J Med Virol 78(8):1035-1042.

Henry SH, Bosch FX, Troxell TC, Bolger PM. 1999. Policy forum: public health. Reducing liver cancer--global control of aflatoxin. Science 286(5449):2453-2454.

Hong Z, Zou S, Giulivi A. 2001. Hepatitis B and its control in Southeast Asia and China. Can Commun Dis Rep 27(suppl 3):31-33. Available: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/01vol27/27s3/27s3k_e.html [accessed 19 May 2010].

IARC (International Agency for Research on Cancer). 2002. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monogr Eval Carcinog Risks Hum 82:171-300.

International Programme on Chemical Safety and WHO. 1998. International Programme on Chemical Safety. Safety evaluation of certain food additives and contaminants. WHO Food Additives Series 40. Available: http://www.inchem.org/documents/jecfa/jecmono/v040je01.htm [accessed 19 May 2010].

Ismail AM, Ziada HN, Sheashaa HA, Shehab El-Din AB. 2009. Decline of viral hepatitis prevalence among asymptomatic Egyptian blood donors: a glimmer of hope. Eur J Int Med 20(5):490-493.

Jafri W, Jafri N, Yakoob J, Islam M, Tirmizi SFA, Jafar T, et al. 2006. Hepatitis B and C: prevalence and risk factors associated with seropositivity among children in Karachi, Pakistan. BMC Infect Dis 6:101; doi:10.1186/1471-2334-6-101 [online 23 June 2006].

Jilg W, Hottentrager B, Weinberger K, Schlottmann K, Frick E, Holstege A, et al. 2001. Prevalence of markers of hepatitis B in the adult German population. J Med Virol 63(2):96-102.

Jutavijittum P, Jiviriyawat Y, Yousukh A, Hayashi S, Toriyama K. 2005. Evaluation of a hepatitis B vaccination program in Chiang Mai, Thailand. Southeast Asian J Trap Med Public Health 36(1):207-212.

Kafi-Abad SA, Rezvan H, Abolghasemi H. 2009a. Trends in prevalence of hepatitis B virus infection among Iranian blood donors, 1998-2007. Transfus Med 19(4): 189-194.

Kafi-Abad SA, Rezvan H, Abolghasemi H, Talebian A. 2009b. Prevalence and trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among blood donors in Iran, 2004 through 2007. Transfusion 49(10):2214-2220.

Khattak M, Salamat N, Bhatti FA, Qureshi TZ 2002. Seroprevalence of hepatitis B, C and HIV in blood donors in northern Pakistan. J Pak Med Assoc 52(9):398-402.

Kiire CF. 1996. The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and sub-tropical Africa. Gut 38(suppl 2):S5-S12.

Kirk GD, Bah E, Montesano R. 2006. Molecular epidemology of human liver cancer: insights into etiology. patho genesis and prevention from The Gambia, West Africa Carcinogenesis 27(10):2070-2082.

Kirk GD, Lesi OA, Mendy M, Akano AO, Sam O, Goedert JJ, et al. 2004. The Gambia Liver Cancer Study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology 39(l):211-219.

Kirk GD, Lesi OA, Mendy M, Szymanska K, Whittle H, Goedert JJ, et al. 2005. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene 24(38):5858-5867.

Kuang S-Y, Lekawanvijit S, Maneekarn N, Thongsawat S, Brodovicz K, Nelson K, et al. 2005. Hepatitis B 1762T/1764A mutations, hepatitis C infection, and codon 249 p53 mutations in hepatocellular carcinomas from Thailand. Cancer Epidemiol Biomarkers Prev 14(2):380-384.

Kuiper-Goodman T. 1995. Mycotoxins: risk assessment and legislation. Toxicol Lett 82-33:853-859.

Lansang M. 1996. Epidemiology and control of hepatitis B infection: perspective from the Philippines, Asia. Gut 38(suppl 2):S43-S47.

Lehman EM, Wilson ML 2009. Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta-analysis. Int J Cancer 124(3):690-697.

Li FQ, Yoshizawa T, Kawamura O, Luo XY, Li YW. 2001. Aflatoxins and fumonisins in corn from the high-incidence area for human hepatocellular carcinoma in Guangxi, China. J Agric Food Chem 49(8):4122-4126.

Lipigorngoson S, Limtrakul P, Suttajit M, Yoshizawa T. 2003. In-house direct cELISA for determining aflatoxin B 1 in Thai corn and peanuts. Food Addit Contam Part A 20(9):838-845.

Magdzik W. 2000. Hepatitis B epidemiology in Poland, Central and Eastern Europe and the newly independent states. Vaccine 18(suppl 1):S13-S16.

Malir F, Ostry V, Grosse Y, Roubal T, Skarkova J, Ruprich J. 2006. Monitoring the mycotoxins in food and their biomarkers in the Czech Republic. Mol Nutr Food Res 50(6):513-518.

Manjula K, Hell K, Fandohan P, Abass A, Bandyopadhyay R. 2009. Aflatoxin and fumonisin contamination of cassava products and maize grain from markets in Tanzania and republic of the Congo. Toxin Rev 28:63; doi:10.1080/15569540802462214 [Online2May2009].

Matee M, Magesa P, Lyamuya E. 2006. Seroprevalence of human immunodeficiency virus, hepatitis B and C viruses and syphilis infections among blood donors at the Muhimbili National Hospital in Dar Es Salaam, Tanzania. BMC Public Health 6:21; doi:10.1186/1471-2458-6-21 [online 30 January 2006].

Mazaheri M. 2009. Determination of aflatoxins in imported rice to Iran. Food Chem Toxicol 47(8):2064-2066.

Mbendi Nlombi C, Longo-Mbenza B, Mbendi Nsukini S, Muyembe Tamfum JJ, Situakibanza Nanituma H, Vangu Ngoma D. 2001. Prevalence of HIV and HBs antigen in blood donors. Residual risk of contamination in blood recipients in East Kinshasa, Democratic Republic of the Congo. Med Trap (Mars) 61(2):139-142.

Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, et al. 2000. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 15(12):1356-1361.

Midio AF, Campos RR, Sabino M. 2001. Occurrence of aflatoxins B1, B2, G1 and G2 in cooked food components of whole meals marketed in fast food outlets of the city of Sao Paulo, SP, Brazil. Food Addit Contam PART A 18(5):445-448.

Miller WC, Shao JF, Weaver DJ, Shimokura GH, Paul DA, Lallinger GJ. 1998. Seroprevalence of viral hepatitis in Tanzanian adults. Trap Med Int Health 3(9):757-763.

Minuk GY, Uhanova J. 2001. Chronic hepatitis B infection in Canada. Can J Infect Dis 12(6):351-356.

Munir M, Saleem M, Malik ZR, Ahmed M, Ali A. 1989. Incidence of aflatoxin contamination in non-perishable food commodities. J Pak Med Assoc 39(6):154-157.

Nakata S, Song P, Duc DD, Nguyen XQ, Murata K, Tsuda F, et al. 1994. Hepatitis C and B virus infections in populations at low or high risk in Ho Chi Minh and Hanoi, Vietnam. J Gastroenterol Hepatol 9(4):416-419.

National Health and Medical Research Council. 1992. The 1990 Australia Market Basket Survey. Canberra:National Health and Medical Research Council.

National Research Council. 1983. Risk Assessment in the Federal Government: Managing the Process. Washington, DC:National Academy Press.

National Research Council. 2008. Science and Decisions: Advancing Risk Assessment. Washington, DC:National Academy Press.

Noviandi CT, Razzazi E, Agus A, Bohm J, Hulan HW, Wedhastri S, et al. 2001. Natural occurrence of aflatoxin B1 in some Indonesian food and feed products in Yogyakarta in year 1998-1999. Mycotoxin Res 17(0):174-177.

Ok HE, Kim HJ, Bo Shim W, Lee H, Bae DH, Chung DH, et al. 2007. Natural occurrence of aflatoxin B1 in marketed foods and risk estimates of dietary exposure in Koreans. J Food Protect 70(12):2824-2828.

Oliveira CA, Goncalves NB, Rosim RE, Fernandes A. 2009. Determination of aflatoxins in peanut products in the northeast region of Sao Paulo, Brazil. Int J Mol Sci 10(1):174-183.

Omer RE, Bakker Ml, van't Veer P, Hoogenboom RL, Polman TH, Alink GM, et al. 1998. Aflatoxin and liver cancer in Sudan. Nutr Cancer 32(3): 174-180.

Parana R, Almeida D. 2005. HBV epidemiology in Latin America. J Clin Virol 34(suppl 1):S130-S133.

Park JW, Kim EK, Kim YB. 2004. Estimation of the daily exposure of Koreans to aflatoxin B1 through food consumption. Food Addit Contam PART A 21(1):70-75.

Pitt Jl, Tomaska L. 2001. Are mycotoxins a health hazard in Australia? Food Austr 53(12):545-559.

Plymoth A, Viviani S, Hainaut P. 2009. Control of hepatocellular carcinoma through Hepatitis B vaccination in areas of high endemicity: perspectives for global liver cancer prevention. Cancer Lett 286(1):15-21.

Qian GS, Ross RK, Yu MC, Yuan JM, Gao YT, Henderson BE. 1994. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 3:3-10.

Resuli B, Prifti S, Kraja B, Nurka T, Basho M, Sadiku E. 2009. Epidemiology of hepatitis B virus infection in Albania. World J Gastroenterol 15(7):849-852.

Roman S, Panduro A, Aguilar-Gutierrez Y, Maldonado M, Vazquez-VanDyck M, Martinez-Lopez E, et al. 2009. A low steady HBsAg seroprevalence is associated with a low incidence of HBV-related liver cirrhosis and hepatocellular carcinoma in Mexico: a systematic review. Hepatol Int 3(2):343-355.

Sales AC, Yoshizawa T. 2005. Updated profile of aflatoxin and Aspergillus section Flavi contamination in rice and its byproducts from the Philippines. Food Addit Contam: Part A 22(5):429-436.

Shephard GS. 2003. Aflatoxin and food safety: recent African perspectives. Toxin Rev 22:267; doi:10.1081/TXR-120024094 [Online 8 November 2003].

Shephard GS 2008. Risk assessment of aflatoxins in food in Africa Food Addit Contam: Part A 25(10):1246-1256.

Shimelis T, Torben W, Medhin G, Tebeje M, Andualm A, Demessie F, et al. 2008. Hepatitis B virus infection among people attending the voluntary counselling and testing centre and anti-retroviral therapy clinic of St Paul's General Specialised Hospital, Addis Ababa, Ethiopia. Sex Transm Infect 84(1):37-41.

Solovey MMS, Somoza C, Cano G, Pacin A, Resnik S. 1999. A survey of fumonisins, deoxynivalenol, zearalenone and aflatoxins contamination in corn-based food products in Argentina. Food Addit Contam Part A 16(8):325-329.

Song E, Yun YM, Park MH, Seo DH. 2009. Prevalence of occult hepatitis B virus infection in a general adult population in Korea. Intervirology 52(2):57-62.

Strosnider H, Azziz-Baumgartner E, Banziger M, Bhat RV, Breiman R, Brune M, et al. 2006. Workgroup report: public health strategies for reducing aflatoxin exposure in developing countries. Environ Health Perspect 114:1898-1903.

Szymahska K, Chen JG, Cui Y, Gong YY, Turner PC, Villar S, et al. 2009. TP53 R249S mutations, exposure to aflatoxin, and occurrence of hepatocellular carcinoma in a cohort of chronic hepatitis B virus carriers from Qidong, China. Cancer Epidemiol Biomark Prev 18(5):1638-1643.

Tajkarimi M, Shojaee Aliabadi F, Salah Nejad M, Pursoltani H, Motallebi AA, Mahdavi H. 2007. Seasonal study of aflatoxin M1 contamination in milk in five regions in Iran. Int J Food Microbiol 116(3):346-349.

Tendon BN, Acharya SK, Tandon A. 1996. Epidemiology of hepatitis B virus infection in India. Gut 38(suppl 2):S56-S59.

Tanprasert S, Somjitta S. 1993. Trend study on HBsAg prevalence in Thai voluntary blood donors. Southeast Asian J Trop Med Public Health 24(suppl 1):43-45.

Tayou CT, Amadou D, Rakia Y, Marc H, Antoine N, Guy M, et al. 2009. Characteristics of blood donors and donated blood in sub-Saharan francophone Africa. Transfusion 49(8):1592-1599.

Torres JR. 1996. Hepatitis B and hepatitis delta virus infection in South America. Gut 38(suppl 2):S48-S55.

Torres Espinosa E, Acuna Askar K, Naccha Torres LR, Montoya Olvera R, Castrellon Santa Anna J. 1995. Quantification of aflatoxins in corn distributed in the city of Monterrey, Mexico. Food Addit Contam 12(3):383-386.

Tswana S, Chetsanga C, Nystrom L, Moyo S, Nzara M, Chieza L 1996. A sero-epidemiological cross-sectional study of hepatitis B virus in Zimbabwe. S Afr Med J 86(1):72-75.

Tuei J, Okoth F, Kasomo A, Ireri E, Kaptich D, Watahi A, et al. 1994. Prevalence of hepatocellular carcinoma, liver cirrhosis and HBV carriers in liver disease patients referred to Clinical Research Centre, Kemri. Afr J Health Sci 1(3):126-128.

Vall Mayans M, Hall AJ, Inskip HM, Chotard J, Lindsay SW, Coromina E, et al. 1990. Risk factors for transmission of hepatitis B virus to Gambian children. Lancet 336(8723):1107-1109.

van Hattum J, Boland GJ, Jansen KG, Kleinpenning AS, van Bommel T, van Loon AM, et al. 2003. Transmission profile of hepatitis B virus infection in the Batam region, Indonesia. Evidence for a predominantly horizontal transmission profile. Adv Exp Med Biol 531:177-183.

Vargas EA, Preis RA, Castro L, Silva CMG. 2001. Co-occurrence of aflatoxins B 1, B 2, G 1, G 2, zearalenone and fumonisin B 1 in Brazilian corn. Food Addit Contam: Part A 18:981; doi:10.1080/02652030110046190 [Online 11 November 2001].

Vasanthi S, Bhat RV. 1998. Mycotoxins in foods--occurrence, health and economic significance and food control measures. Ind J Med Res 108:212-224.

Wang JS, Huang T, Su J, Liang F, Wei Z, Liang Y, et al. 2001. Hepatocellular carcinoma and aflatoxin exposure in Zhuqing Village, Fusui County, People's Republic of China. Cancer Epidemiol Biomarkers Prev 10(2):143-146.

Wang J, Liu XM. 2007. Contamination of aflatoxins in different kinds of foods in China. Biomed Environ Sci 20(6):483-487.

WHO. 2005. Vaccine Product Selection Menu. A Guide for National Immunization Managers when Introducing GAVI/The Vaccine Fund Supported Vaccines. Available: http://www.who.int/immunization_delivery/new_vaccines/4.Coreinformation_Hepatitis%20B.pdf [accessed 27 April 2010].

WHO. 2006. Global Environment Monitoring System--Food Contamination Monitoring and Assessment Programme (GEMS/Food). Available: http://www.who.int/foodsafety/chem/gems/en/index1.html [accessed 20 August 2009].

WHO. 2007. Western Pacific Regional Plan for Hepatitis B Control through Immunization. Manila, Philippines:World Health Organization, Regional Office for the Western Pacific.

WHO. 2008. The Global Burden of Disease: 2004 Update. Geneva:World Health Organization. Available: http://www.who.int/healthinfo/global_burden_disease/2004_report__update/en/index.html [accessed 27 April 2010].

Wild CP, Gong YY. 2010. Mycotoxins and human disease: a largely ignored global health issue. Carcinogenesis 31:71-82.

Wild CP, Hall AJ, 2000. Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res Rev Mutat Res 462(2-3):381-393.

Wild CP, Montesano R. 2009. A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. Cancer Lett 286(1):22-28.

Williams JH. 2008. Institutional stakeholders in mycotoxin issues--past, present and future. In: Mycotoxins: Detection Methods, Management, Public Health and Agricultural Trade (Leslie JF, Bandyopadhyay R, Visconti A, eds). Oxfordshire, UK:CAB International, 349-358.

Williams J, Nokes DJ, Medley GF, Anderson RM. 1996. The transmission dynamics of hepatitis B in the UK: a mathematical model for evaluating costs and effectiveness of immunization programmes. Epidemiol Infect 116:71-89.

Wu F. 2004. Mycotoxin risk assessment for the purpose of setting international regulatory standards. Environ Sci Tec hnol 38(15):4049-4055.

Wu F, Khiangwiset P. 2010. Health economic impacts and cost-effectiveness of aflatoxin reduction strategies in Africa: case studies in biocontrol and postharvest interventions. Food Addit Contam: Part A 27:496; doi 10.1080/19440040903437865 [Online 4 April 2010].

Yeh FS, Yu MC, Mo CC, Luo S, Tong MJ, Henderson BE. 1989. Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. Cancer Res 49(9):2506-2509.

Youssef A, Yano Y, Utsumi T, abd El-alah EM, abd El-Hameed AE, Serwah AH, et al. 2009. Molecular epidemiological study of hepatitis viruses in Ismailia, Egypt. Intervirology 52(3):123-131.

Zhang J, Zou S, Giulivi A. 2001. Hepatitis B in Canada. Can Common Dis Rep 27(suppl 3):10-12. Available: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/01vol27/27s3/27s3e_e.html [accessed 27 April 2010].

Address correspondence to F. Wu, Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh, 100 Technology Dr., Rm 560, Pittsburgh, PA 15219 USA. Telephone: (412) 624-1306. Fax: (412) 624-3040. E-mail: few8@pitt.edu

We thank T Kensler (University of Pittsburgh), J. Groopman (Johns Hopkins University), and C. Wild (International Agency for Research on Cancer) for their helpful comments.

This work was funded by the Bill and Melinda Gates Foundation and the National Institutes of Health (KL2 RR024153).

The authors' salaries are supported in part by the Bill & Melinda Gates Foundation.

Received 26 August 2009; accepted 19 February 2010.

Yan Liu and Felicia Wu

Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
COPYRIGHT 2010 National Institute of Environmental Health Sciences
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research
Author:Liu, Yan; Wu, Felicia
Publication:Environmental Health Perspectives
Article Type:Clinical report
Geographic Code:1USA
Date:Jun 1, 2010
Words:8886
Previous Article:Pesticide use and cutaneous melanoma in pesticide applicators in the agricultural heath study.
Next Article:Association of exposure to phthalates with endometriosis and uterine leiomyomata: findings from NHANES, 1999-2004.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters